We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+1.98%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$479M
AUM Growth
+$31.4M
(+7%)
Cap. Flow
+$69.7M
Cap. Flow
% of AUM
14.56%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
82
New
23
Increased
27
Reduced
15
Closed
14
Top Buys
| 1 |
ETNB
89bio
ETNB
|
+$12.4M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$11.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$9.19M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$8.1M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$7.71M |
Top Sells
| 1 |
Pliant Therapeutics
PLRX
|
+$17.3M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$15M |
| 3 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
+$9.72M |
| 4 |
Scholar Rock
SRRK
|
+$7.92M |
| 5 |
Cogent Biosciences
COGT
|
+$7.18M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $34.7M | 7.24% |
545,872
+29,858
| +6% | +$1.79M |
|
|
MRUS
2
DELISTED
Merus
MRUS
| $34.1M | 7.13% |
811,021
+130,176
| +19% | +$5.68M |
|
3
Nuvalent
NUVL
$9.81B
| $31.1M | 6.5% |
439,018
+39,004
| +10% | +$3.05M |
|
|
AKRO
4
DELISTED
Akero Therapeutics
AKRO
| $29.1M | 6.09% |
719,992
-19,571
| -3% | -$830K |
|
5
Insmed
INSM
$23.5B
| $24.5M | 5.12% |
321,366
-50,864
| -14% | -$3.89M |
|
|
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
| $19.6M | 4.1% |
1,698,984
+1,086,811
| +178% | +$11.1M |
|
7
Veracyte
VCYT
$4.68B
| $18.8M | 3.93% |
633,832
+130,551
| +26% | +$4.98M |
|
8
Rhythm Pharmaceuticals
RYTM
$7.44B
| $17.9M | 3.74% |
337,605
+63,709
| +23% | +$3.53M |
|
9
Syndax Pharmaceuticals
SNDX
$2.11B
| $16.1M | 3.36% |
1,309,224
+78,824
| +6% | +$1.11M |
|
10
UroGen Pharma
URGN
$1.88B
| $15.3M | 3.19% |
1,381,158
+260,685
| +23% | +$2.78M |
|
|
RNAM
11
DELISTED
Avidity Biosciences
RNAM
| $12.1M | 2.54% |
411,312
-132,339
| -24% | -$4.12M |
|
|
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
| $11.9M | 2.48% |
+166,417
| New | +$8.1M |
|
13
Ascendis Pharma A/S
ASND
$17.4B
| $11.8M | 2.47% |
75,751
+24,260
| +47% | +$3.47M |
|
14
Disc Medicine
IRON
$2.86B
| $11.7M | 2.45% |
236,471
+126,090
| +114% | +$7.01M |
|
|
15
Oric Pharmaceuticals
ORIC
$1.11B
| $11.5M | 2.4% |
2,060,240
+881,940
| +75% | +$7.71M |
|
|
ETNB
16
DELISTED
89bio
ETNB
| $11M | 2.29% |
1,510,498
+1,413,987
| +1,465% | +$12.4M |
|
17
Erasca
ERAS
$6.27B
| $10.1M | 2.11% |
7,367,996
-175,905
| -2% | -$302K |
|
18
Wave Life Sciences
WVE
$1.15B
| $8.49M | 1.77% |
1,050,374
+441,477
| +73% | +$4.83M |
|
|
19
Neurocrine Biosciences
NBIX
$17.2B
| $8.03M | 1.68% |
+72,583
| New | +$9.19M |
|
20
Travere Therapeutics
TVTX
$5.24B
| $7.33M | 1.53% |
408,849
+131,484
| +47% | +$2.67M |
|
21
Gossamer Bio
GOSS
$65.1M
| $6.95M | 1.45% |
6,320,684
+148,837
| +2% | +$172K |
|
22
Gilead Sciences
GILD
$162B
| $6.95M | 1.45% |
62,029
+52,029
| +520% | +$5.37M |
|
|
BBOT
23
BridgeBio Oncology
BBOT
$691M
| $6.93M | 1.45% |
613,393
+100,024
| +19% | +$1.08M |
|
24
Elutia
ELUT
$40.7M
| $6.76M | 1.41% |
2,670,056
+887,785
| +50% | +$2.68M |
|
25
Praxis Precision Medicines
PRAX
$9.02B
| $6.29M | 1.31% |
166,074
+93,558
| +129% | +$5.84M |
|
Similar funds
BOTOTLSJU
EFG
LA
EPIMS
CFP
USAA
OMC
AIA